




Curriculum Vitae

* CV must be written in English

Personal Information	
Title (i.e. Pf., Dr., etc.)	Pf.
Name (First Name/ Middle Name /Last Name)	Hyeong Ho / Jo
Degree (i.e. MD, MSc, PhD, etc.)	MD
Country	South Korea
Affiliation	Daegu catholic university school of medicine
E-mail	johh@cu.ac.kr
	
Educational Background	
Kosin University College of Medicine, Busan, Korea Doctor of Medicine, Feb. 2012 Daegu Catholic University School of Medicine, Daegu, Korea Masters in medical science, Feb. 2021	
Professional Career	
Kosin University Gospel Hospital, Busan, Korea Intern, General Medicine internship program, Mar 2012 - Feb 2013 Daegu Catholic University Medical center, Daegu, Korea Resident, Internal Medicine Residency program, Mar 2013 - Feb 2017 Daegu Catholic University Medical center, Daegu, Korea Clinical & Research Fellow in Gastroenterology, May 2020 - Feb 2021 Seoul National University Bundang Hospital, Seongnam, Korea Clinical & Research Fellow in Gastroenterology, Mar 2021 - Feb 2022 Daegu Catholic University School of Medicine, Daegu, Korea Assistant professor in internal medicine, Mar 2022-	
Research Field	
The Korean Association for the study of Intestinal Disease The Korean College of Helicobacter and Upper Gastrointestinal Research The Korean Society of Neurogastroenterology and Motility	
Main Scientific Publications	
<i>Main Achievements (10 max)</i> Jo, H.H., Gastric cancer and metabolic syndrome. KMJ, 2024. 39(1): p. 26-34. Jo, H.H., et al., The Clinicopathological Features of Mixed Carcinoma in 7,215 Patients with Gastric Cancer in a Tertiary Hospital in South Korea. Gut and Liver, 2023. 17(5): p. 731-740. Bae, J.H., et al., Efficacy of 7-day Tailored Therapy for Helicobacter pylori Eradication based on Clarithromycin Resistance. Korean J Gastroenterol, 2023. 82(1): p. 10-17. Jo, H.H., et al., Impact of Body Mass Index on Survival Depending on Sex in 14,688 Patients with Gastric Cancer in a Tertiary Hospital in South Korea. Gut and Liver, 2023. 17(2): p. 243-258. Jo, H.H., et al., Value of Fecal Calprotectin Measurement During the Initial Period of Therapeutic Anti-Tubercular Trial. Clin Endosc, 2022. 55(2): p. 256-262.	

- Please note that the above information will be used for the introduction of speakers for the IMKASID 2025 website and announcements. Also, it will be provided to the session chairpersons before your lecture.

- Please complete this form (no more than 2 pages) and return it to the IMKASID 2025 secretariat by email, info@imkasid.kr.